Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
SynAct Pharma AB ( (SE:SYNACT) ) just unveiled an update.
SynAct Pharma AB has announced that Edison Investment Research Ltd., a UK-based firm, has initiated coverage of the company. This collaboration is expected to enhance SynAct Pharma’s visibility in the pharma and biotech industry, potentially impacting its market positioning and providing stakeholders with valuable insights into its operations.
More about SynAct Pharma AB
SynAct Pharma AB is a clinical-stage biotechnology company that focuses on resolving inflammation through the selective activation of the melanocortin system. The company offers a broad portfolio of oral and injectable selective melanocortin agonists designed to induce anti-inflammatory and inflammation resolution activity, aiding patients in achieving immune balance.
Average Trading Volume: 174,485
Technical Sentiment Signal: Buy
Current Market Cap: SEK1.18B
For an in-depth examination of SYNACT stock, go to TipRanks’ Overview page.